In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by Canakinumab has been shown to significantly reduce lung cancer incidence and mortality [37] and similarly, administration of IL-1Ra reduced liver and lung metastasis [32, 33]. This evidence concerns the gene IL1B and lung carcinoma.